UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000023245 |
|---|---|
| Receipt number | R000026787 |
| Scientific Title | Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients |
| Date of disclosure of the study information | 2016/07/25 |
| Last modified on | 2017/04/12 13:06:00 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients
Acronym
Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients
Scientific Title
Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients
Scientific Title:Acronym
Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients
Region
| Japan |
Condition
Condition
Type 2 diabetes mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to compare efficacy and safety of dulaglutide in type 2 diabetes mellitus patients who are formerly treated with sitagliptin
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Change of HbA1c,body weight at the 12th and the 24th week.
Key secondary outcomes
Change of data shown below at the 12th and the 24th week.
AST, ALT, gamma-GTP, LDL-C, HDL-C,TG, non-HOL-C, serum creatinine, serum UA
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
The patients are treated with dulaglutide instead of sitagliptin from the start to the 24th week.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Type 2 diabetes with HbA1c =/> 6.5%
Key exclusion criteria
1. Type 1 diabetes
2. Patients with severe renal failure or liver dysfunction
3. Patients with drug allergy for ipraglifrozin
4. Patients with history of diabetec ketosis
5. Patients with shick day
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tomoyuki Iwasaki |
Organization
Iwasaki Naika Clinic
Division name
Endocrinology and Metabolism
Zip code
Address
1-1-5-1F Kamihoshikawa, Hodogayaku, Yokohama, Kanagawa, Japan
TEL
045-442-6475
iwasaki11111@gmail.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tomoyuki Iwasaki |
Organization
Iwasaki Naika Clinic
Division name
Endocrinology and Metabolism
Zip code
Address
1-1-5-1F Kamihoshikawa, Hodogayaku, Yokohama, Kanagawa, Japan
TEL
045-442-6475
Homepage URL
iwasaki11111@gmail.com
Sponsor or person
Institute
Iwasaki Naika Clinic
Institute
Department
Personal name
Funding Source
Organization
Iwasaki Naika Clinic
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
岩崎内科クリニック
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 07 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2016 | Year | 07 | Month | 20 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 07 | Month | 25 | Day |
Last follow-up date
| 2017 | Year | 04 | Month | 28 | Day |
Date of closure to data entry
| 2017 | Year | 04 | Month | 28 | Day |
Date trial data considered complete
| 2017 | Year | 04 | Month | 28 | Day |
Date analysis concluded
| 2017 | Year | 05 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2016 | Year | 07 | Month | 20 | Day |
Last modified on
| 2017 | Year | 04 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026787
